Using the AS04C-adjuvanted hepatitis B vaccine in patients classified as non-responders.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-03-04 DOI:10.1093/trstmh/trad078

Sara Fernández Sánchez-Escalonilla, Jesus Gonzalez-Rubio, Alberto Najera, Jose Miguel Cantero Escribano, Francisco Jesús Molina Cabrero, Jesús García Guerrero

{"title":"Using the AS04C-adjuvanted hepatitis B vaccine in patients classified as non-responders.","authors":"Sara Fernández Sánchez-Escalonilla, Jesus Gonzalez-Rubio, Alberto Najera, Jose Miguel Cantero Escribano, Francisco Jesús Molina Cabrero, Jesús García Guerrero","doi":"10.1093/trstmh/trad078","DOIUrl":null,"url":null,"abstract":"Background: Chronic hepatitis B (HB) remains a significant global health concern, despite the widespread availability of the HB vaccine. While the standard vaccine demonstrates an impressive serological response rate exceeding 90%, a subset of individuals exhibit suboptimal immunity. This study aims to elucidate the efficacy of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness.Methods: Conducted at the Preventive Medicine Service of the University Albacete Hospital in Spain from 2017 to 2021, this single-center observational study enrolled 195 patients. Among them, 126 (65%) were classified as non-responders following one or two complete standard vaccination courses.Results: After the administration of a complete four-dose regimen of the AS04C-adjuvanted vaccine, 73.81% of non-responder patients exhibited antibody titers indicative of robust immunity (anti-HBs >10).Conclusions: These findings underscore the pivotal role of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness, emphasizing its potential as a crucial tool in augmenting immunization strategies for various populations. This includes non-responders to standard vaccination, individuals with chronic kidney disease, those requiring seroprotection due to factors like immunosuppression or occupational hazards, as well as patients for whom conventional revaccination strategies have proven futile. Additional research is needed to expand on the promising results obtained through our protocol.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/trstmh/trad078","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chronic hepatitis B (HB) remains a significant global health concern, despite the widespread availability of the HB vaccine. While the standard vaccine demonstrates an impressive serological response rate exceeding 90%, a subset of individuals exhibit suboptimal immunity. This study aims to elucidate the efficacy of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness.

Methods: Conducted at the Preventive Medicine Service of the University Albacete Hospital in Spain from 2017 to 2021, this single-center observational study enrolled 195 patients. Among them, 126 (65%) were classified as non-responders following one or two complete standard vaccination courses.

Results: After the administration of a complete four-dose regimen of the AS04C-adjuvanted vaccine, 73.81% of non-responder patients exhibited antibody titers indicative of robust immunity (anti-HBs >10).

Conclusions: These findings underscore the pivotal role of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness, emphasizing its potential as a crucial tool in augmenting immunization strategies for various populations. This includes non-responders to standard vaccination, individuals with chronic kidney disease, those requiring seroprotection due to factors like immunosuppression or occupational hazards, as well as patients for whom conventional revaccination strategies have proven futile. Additional research is needed to expand on the promising results obtained through our protocol.

查看原文本刊更多论文

在分类为无应答的患者中使用AS04C佐剂乙肝疫苗。

背景：慢性乙型肝炎（HB）仍然是一个重要的全球健康问题，尽管乙肝疫苗广泛可用。虽然标准疫苗显示出超过90%的令人印象深刻的血清学应答率，但也有一部分人表现出次优免疫力。本研究旨在阐明AS04C佐剂乙肝疫苗在解决无反应性方面的疗效。方法：这项单中心观察性研究于2017年至2021年在西班牙阿尔巴塞特大学医院预防医学服务中心进行，共招募了195名患者。其中，126人（65%）在一到两个完整的标准疫苗接种过程后被归类为无应答者。结果：在施用AS04C佐剂疫苗的完整四剂方案后，73.81%的无应答患者表现出表明强大免疫的抗体滴度（抗-HBs>10）。结论：这些发现强调了AS04C佐剂乙肝疫苗在解决无反应性方面的关键作用，强调了其作为加强不同人群免疫策略的关键工具的潜力。这包括对标准疫苗接种没有反应的人、患有慢性肾脏疾病的人、因免疫抑制或职业危害等因素而需要血清保护的人，以及传统重新接种策略被证明无效的患者。需要进一步的研究来扩大通过我们的方案获得的有希望的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.